一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Candidate tumor-specific CD8(+) T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis.
Candidate tumor-specific CD8(+) T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
从恶性胸腔积液(MPE)中分离肿瘤特异性T细胞及其抗原受体(TCR)可能有助于为晚期肺癌患者开发TCR转导的过继性细胞免疫治疗产品。
然而,MPE中肿瘤特异性T细胞的特征和标志物在很大程度上尚未明确。为此,为了确定CD8+ T细胞的表型和抗原特异性,我们对三名晚期肺癌患者的样本进行了单细胞RNA和TCR测序。对总共4,983个CD8+ T细胞进行降维分析,揭示了10个细胞簇,包括初始、记忆和耗竭表型。
我们特别关注耗竭T细胞簇,并测试了它们对预测自自体癌细胞系的新抗原的TCR反应性。从其中一名患者中鉴定出四种针对同一新抗原的不同TCR,以及一种针对自体细胞系的孤儿TCR。相对于其他T细胞,肿瘤特异性T细胞的差异基因表达分析鉴定出CXCL13为肿瘤特异性T细胞表达的候选基因。除了表达CXCL13外,肿瘤特异性T细胞在共表达PDCD1(PD-1)/ TNFRSF9(4-1BB)的T细胞中占更高比例。
此外,对伴有MPE的晚期肺癌患者进行的流式细胞术分析记录显示,在57名腺癌患者亚组中,PD-1/4-1BB高表达者预后更好(p = .039)。这些数据表明,PD-1/4-1BB共表达可能识别MPE中的肿瘤特异性CD8+ T细胞,这些细胞与患者预后相关。(233词)。
Isolation of tumor-specific T cells and their antigen receptors (TCRs) from malignant pleural effusions (MPE) may facilitate the development of TCR-transduced adoptive cellular immunotherapy products for advanced lung cancer patients.
However, the characteristics and markers of tumor-specific T-cells in MPE are largely undefined. To this end, to establish the phenotypes and antigen specificities of CD8 + T cells, we performed single-cell RNA and TCR sequencing of samples from three advanced lung cancer patients. Dimensionality reduction on a total of 4,983 CD8 + T cells revealed 10 clusters including naïve, memory, and exhausted phenotypes.
We focused particularly on exhausted T cell clusters and tested their TCR reactivity against neoantigens predicted from autologous cancer cell lines. Four different TCRs specific for the same neoantigen and one orphan TCR specific for the autologous cell line were identified from one of the patients. Differential gene expression analysis in tumor-specific T cells relative to the other T cells identified CXCL13 , as a candidate gene expressed by tumor-specific T cells.
In addition to expressing CXCL13 , tumor-specific T cells were present in a higher proportion of T cells co-expressing PDCD1 (PD-1)/ TNFRSF9 (4-1BB).
Furthermore, flow cytometric analyses in advanced lung cancer patients with MPE documented that those with high PD-1/4-1BB expression have a better prognosis in the subset of 57 adenocarcinoma patients ( p = . 039). These data suggest that PD-1/4-1BB co-expression might identify tumor-specific CD8 + T cells in MPE, which are associated with patients' prognosis. (233 words).
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。